Goodwin advised resTORbio in the transaction resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of…
resTORbio’s $97.8 Million Initial Public Offering
![](https://globallegalchronicle.com/wp-content/uploads/2018/02/ae1b9b1177.jpeg)